Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Endocrine-Related Cancer

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1677/ERC.1.00945PMID 15947110
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma

  2005cited by this paper
• Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.

  2004cited by this paper
• Role of proliferation in HER2 status predicted response to doxorubicin

  2003cited by this paper
• Expert Commentary.

  2002cited by this paper
• Endocrine therapy of breast cancer.

  2002cited by this paper
• The biology of neoadjuvant chemotherapy for breast cancer.

  2002cited by this paper
• Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

  2001cited by this paper
• Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

  2001cited by this paper
• Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.

  2000cited by this paper
• p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

  2000cited by this paper
• Prediction of response to primary chemotherapy for operable breast cancer.

  1999cited by this paper
• Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer

  1999cited by this paper
• Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  1998cited by this paper
• Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study

  1997cited by this paper
• Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

  1996cited by this paper
• Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.

  1996cited by this paper
• Tumor proliferative activity and response to first-line chemotherapy in advanced breast cancer.

  1994cited by this paper
• Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.

  1993cited by this paper
• Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype.

  1991cited by this paper
• Changes in cell kinetics induced by primary chemotherapy in breast cancer

  1991cited by this paper
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

  1991cited by this paper
• Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.

  1990cited by this paper
• Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.

  1989cited by this paper
• Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line.

  1987cited by this paper
• Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

  1985cited by this paper

• Expression of p53 and ki-67 in Breast Carcinomas and Their Association with Histopathological Type, Grade, and Stage

  2024cites this paper
• Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systematic review and meta-analysis

  2023cites this paper
• Assessment of Proliferation Index and Pathological Features as Prognostic Potential of Breast Cancer in Ethiopia

  2019cites this paper
• Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR

  2018cites this paper
• 3D Pseudocontinuous Arterial Spin-Labeling MR Imaging in the Preoperative Evaluation of Gliomas

  2017cites this paper
• Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer

  2017cites this paper
• Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer.

  2016cites this paper
• Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer : Use as an Endpoint to Support Accelerated Approval

  2014cites this paper
• Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.

  2013cites this paper
• Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

  2012cites this paper
• Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer.

  2011cites this paper
• Neoadjuvant systemic treatment of breast cancer

  2011cites this paper
• Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.

  2011cites this paper
• Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer

  2011cites this paper
• Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

  2011cites this paper
• The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen

  2011cites this paper
• Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer.

  2011cites this paper
• High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy

  2010cites this paper
• Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients

  2010influential citation
• Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.

  2010cites this paper
• EXPRESSÃO DE MARCADORES MOLECULARES PREDITIVOS DE RESPOSTA À TERAPÊUTICA NEOADJUVANTE EM CÂNCER DE MAMA EM AMOSTRAS TUMORAIS

  2010cites this paper
• Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer

  2009cites this paper
• Preoperative chemo- and endocrine therapy.

  2009cites this paper
• Systemtherapie des Mammakarzinoms

  2009cites this paper
• Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity

  2008cites this paper
• Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions.

  2008cites this paper
• Medroxyprogesterone and tamoxifen augment anti‐proliferative efficacy and reduce mitochondria‐toxicity of epirubicin in FM3A tumor cells in vitro

  2007cites this paper
• Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer

  2007cites this paper
• Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer.

  2007cites this paper
• Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer

  2006cites this paper
• Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients

  2006cites this paper
• Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.

  2006cites this paper
• Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.

  2006influential citation
• Is pathologic complete response a valid surrogate parameter of treatment efficacy in HER2 positive breast cancer patients undergoing primary chemotherapy plus trastuzamab?

  2005cites this paper
• Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures

  2005cites this paper